Skip to main content

Table 3 Concordance between STRAT4 and IHC for two or more biomarkers

From: Comparison of breast cancer surrogate subtyping using a closed-system RT-qPCR breast cancer assay and immunohistochemistry on 100 core needle biopsies with matching surgical specimens

Comparisons Biomarkers OPA% (95% CI)
STRAT4 vs IHC, both CNB 4-waysa STRAT4 vs 4-waysa IHC
(ER, PR, Ki-67 and HER2)
57 (46.7–66.9)
3-waysa STRAT4 vs 3-waysa IHC
(ER, Ki-67 and HER2)
64 (53.8–73.4)
2-waysa STRAT4 vs 2-waysa IHC (ER and HER2) 84 (75.3–90.6)
2-waysa STRAT4 vs 2-waysa IHC (ER and Ki-67) 74 (64.3–82.3)
STRAT4 vs IHC, both surgical specimen 4-waysa STRAT4 vs 4-waysa IHC
(ER, PR, Ki-67 and HER2)
66 (55.8–75.2)
3-waysa STRAT4 vs 3-waysa IHC
(ER, Ki-67 and HER2)
70 (60.0–78.8)
2-waysa STRAT4 vs 2-waysa IHC (ER and HER2) 87 (78.8–93.0)
2-waysa STRAT4 vs 2-waysa IHC (ER and Ki-67) 75 (65.3–83.1)
  1. aAgreement with respect to 4-ways analysis means total concordance with respect to all four biomarkers (ER, PR, Ki-67, and HER2), 3-ways that all three biomarkers match, etc.